BOLT:NSD-Bolt Biotherapeutics Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 3.76

Change

-0.24 (-6.00)%

Market Cap

USD 0.15B

Volume

0.24M

Avg Analyst Target

USD 31.60 (+740.43%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Bolt Biotherapeutics Inc (BOLT) Stock Analysis:
Based on the Bolt Biotherapeutics Inc stock forecasts from 4 analysts, the average analyst target price for Bolt Biotherapeutics Inc is USD 31.60 over the next 12 months. Bolt Biotherapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Bolt Biotherapeutics Inc is Slightly Bearish, which is based on 2 positive signals and 4 negative signals. At the last closing, Bolt Biotherapeutics Inc’s stock price was USD 3.76. Bolt Biotherapeutics Inc’s stock price has changed by -0.03% over the past week, -0.93% over the past month and +0.00% over the last year.

About

Bolt Biotherapeutics, Inc., a clinical-stage immuno-oncology company, engages in the discovery, development, and commercialization of pharmaceutical products. The company develops BDC-1001, a human epidermal growth factor receptor 2 (HER2) for the treatment of patients with HER2- ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-01-20 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

-6.55 (-3.76%)

USD83.01B 12.27 12.33
REGN Regeneron Pharmaceuticals Inc

-3.73 (-0.60%)

USD66.47B 9.89 8.23
VRTX Vertex Pharmaceuticals Incorpo..

-2.23 (-0.97%)

USD58.90B 27.78 15.97
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BNTX BioNTech SE

-5.13 (-3.17%)

USD39.21B 5.08 5.67
BGNE BeiGene Ltd

+14.52 (+6.13%)

USD24.26B N/A N/A
SGEN Seagen Inc

+0.51 (+0.38%)

USD23.82B 55.02 44.86
GMAB Genmab A/S

-0.36 (-1.04%)

USD23.35B 53.31 6.21
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A
RPRX Royalty Pharma plc

-0.66 (-1.65%)

USD17.17B 20.75 11.89

ETFs Containing BOLT

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -23.27% 29% F 13% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -23.27% 29% F 13% F
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 0.15B 41% F 30% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 0.63 97% A+ 96% A
Price / Cash Flow Ratio -3.12 35% F 63% D
EV/EBITDA 0.18 74% C 95% A
Management Effectiveness  
Return on Equity -64.71% 43% F 23% F
Return on Invested Capital 65.23% 95% A 97% A+
Return on Assets -26.13% 47% F 14% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 6.86 21% F 12% F
Short Percent 19.28% 5% F 8% F
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector